FAVIPIRAVIR
Favipiravir-RTP binds to and inhibits RNA-dependent RNA polymerase (RdRp), which ultimately prevents viral transcription and replication.It is indicated among adults (age equal or greater then18years) in the treatment of mild to moderate cases of covid-19.
Oral; 1800mg twice daily for first day than 800mg twice daily for maximum period of 14 days.
Pregnancy, lactating women, severe renal impairment, severe hepatic impairment, hypersensitivity to active substance.
Paediatric: Not studied in pediatrics age group. Pregnancy: Contraindicated. Lactation: Contraindicated. Elderly: use with caution.
Increased blood uric acid level, diarrhea, decrease of neutrophil count, increased SGOT, increased SGPT.
Pyrazinamide, repaglinide, theophylline, sulindac, famciclovir.
